

## AMENDMENTS

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Presently amended) An immunopotentiating composition heteroconjugate comprising:
  - (a) an immunopotentiating protein a monoclonal antibody directed against non-polymorphic TcR-associated CD3 chains,  $\gamma$ ,  $\delta$ ,  $\epsilon$  or  $\zeta$ ; and
  - (b) a second compoundprotein having an epitope against which a cellular or humoral immune response is desired,

wherein said monoclonal antibody and said second protein are conjugated.
2. (Canceled) The composition of claim 1, wherein the immunopotentiating protein comprises a protein derived from microorganisms.
3. (Canceled) The composition of claim 2, wherein the protein derived from microorganisms comprises a bacterial protein.
4. (Canceled) The composition of claim 3, wherein the bacterial protein comprises a staphylococcal enterotoxin.
5. (Canceled) The composition of claim 1, wherein the immunopotentiating protein comprises a monoclonal antibody directed against a T cell activation molecule on the cell surface of a T cell.
6. (Canceled) The composition of claim 5, wherein the T cell activation molecule comprises a variable or constant region epitope expressed on an antigen specific T cell receptor polymorphic TcR  $\alpha$ ,  $\beta$ ,  $\gamma$  or  $\delta$  chain.

7. (Canceled) The composition of claim 5, wherein the monoclonal antibody is directed against non-polymorphic TcR-associated CD3 chains,  $\gamma$ ,  $\delta$ ,  $\epsilon$  or  $\zeta$ .
8. (Original) The composition of claim 7, wherein the monoclonal antibody comprises OKT3, SP34, or 64.1.
9. (Canceled) The composition of claim 5, wherein the monoclonal antibody is directed against T cell surface antigens distinct from, and not physically associated on the cell surface with, TcR.
10. (Canceled) The composition of claim 9, wherein the monoclonal antibody is directed against Thy-1.
11. (Canceled) The composition of claim 9, wherein the monoclonal antibody is directed against an activation epitope expressed on a member of the Ly-6 protein family.
12. (Canceled) The composition of claim 9, wherein the monoclonal antibody(s) is directed against human CD2.
13. (Canceled) The composition of claim 9, wherein the monoclonal antibody is directed against CD28.
14. (Withdrawn/presently amended) The composition of claim 1, wherein the immunopotentiating proteinmonoclonal antibody is a bispecific agent, wherein one arm is specific for a T-cell activation epitopesaid non-polymorphic TcR-associated CD3 chains,  $\gamma$ ,  $\delta$ ,  $\epsilon$  or  $\zeta$ , and the other arm specific for a T cell subset specific epitope.
15. (Withdrawn/presently amended) The composition of claim 14, wherein the bispecific agentmonoclonal antibody comprises a union of two monoclonal antibodies, one directed individually against CD3, the other against CD4.

16. (Original) The composition of claim 1, wherein the second protein comprises a peptide of from about 8 to about 100 amino acids in length.
17. (Original) The composition of claim 1, wherein the second protein comprises a peptide of from 8 to about 50 amino acids in length.
18. (Original) The composition of claim 1, wherein the second protein comprises a peptide derived from a tumor-specific or tumor-associated epitope.
19. (Original) The composition of claim 1, wherein the second protein comprises a peptide derived from a viral-specific or viral-associated epitope.
20. (Withdrawn) The composition of claim 1, wherein the second protein comprises a peptide with an amino acid sequence homologous to that derived from a gene in a bacteria, fungus, protozoal or metazoal parasite.
21. (Original) The composition of claim 19, wherein the viral-specific or viral-associated epitope comprises an amino acid sequence found on the surface of an HIV virus or which is specific for HIV infected cells.
22. (Original) The composition of claim 21, wherein the peptide composition of the viral-specific epitope comprises an epitope from the gp120 envelope protein of HIV-1.
23. (Original) The composition of claim 22, wherein the gp120 envelope protein epitope comprises peptides 18, T1, or T2.
24. (Original) The composition of claim 19, wherein the viral-specific epitope comprises amino acid sequences homologous with those expressed on the surface of human hepatitis virus.

25. (Withdrawn) The composition of claim 19, wherein the viral-specific epitope comprises amino acid sequences homologous with those expressed on the cell surface of viruses causing influenza.
26. (Original) The composition of claim 1, wherein the immunopotentiating protein and the second protein are conjugated by crosslinking them to each other.
27. (Canceled) The composition of claim 1, wherein the second compound comprises a protein.
28. (Presently amended) The composition of claim 271, wherein the second protein includes an amino acid sequence against which an immune response is desired.
29. (Canceled) The composition of claim 1, further defined as a heteroconjugate composition wherein the immunopotentiating protein is conjugated with the second compound to form a heteroconjugate agent.